M. Geirnaert

A comprehensive bone-health management approach for men with prostate cancer receiving androgen deprivation therapy.

W. Leslie, P. Czaykowski, C. E. Lee, 2011, Current oncology.

Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia

M. Seftel, M. Geirnaert, J. Nam, 2018, Journal of medical economics.

Outpatient oral anticancer agent utilization and costs in Manitoba from 2003 to 2016: a population-based study

M. Yogendran, A. Katz, Christine Leong, 2021, Canadian Journal of Public Health.

Off-label infusion of biosimilar bevacizumab: A provincial experience

S. Niraula, M. Geirnaert, J. Howarth, 2020, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia

T. Whiteside, S. Gibson, J. Johnston, 2022, BMC cancer.

Building a National Reassessment Process for Oncology Drugs: Lessons Learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration through a Simulated Reassessment Exercise

A. Denburg, Marianne Taylor, M. Trudeau, 2021, Current oncology.

Descriptive analysis of dosing and outcomes for patients with ibrutinib-treated relapsed or refractory chronic lymphocytic leukemia in a Canadian centre.

K. Uminski, J. Johnston, V. Banerji, 2019, Current oncology.

An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC)

M. Geirnaert, V. Nguyen, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Canada’s First Joint Oncology-Allergy Clinic: Successful Desensitization to Trastuzumab Following Severe Anaphylactic Reaction in Which Epinephrine Was Inappropriately Withheld

M. Geirnaert, Brady J. Anderson, L. McKibbin, 2023, Current oncology.

International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions

M. D. de Lemos, Esin Aysel Kandemir, L. Nakashima, 2022, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Development of a Multi-Criteria Decision Analysis Rating Tool to Prioritize Real-World Evidence Questions for the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) Collaboration

F. Dionne, A. Denburg, Marianne Taylor, 2023, Current Oncology.

Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade

K. Uminski, S. Gibson, J. Johnston, 2023, Current oncology.

Effectiveness and Safety of Immune Checkpoint Inhibitors in Cancer Patients With Autoimmune Disease: A Retrospective Cohort Study

M. Geirnaert, Grace Musto, Jeffrey Graham, 2023, Journal of immunotherapy.